Shots:

• AstraZeneca to receive $270M on completion. The transaction is expected to be close in Q4'21 while Covis will also pay an ongoing development cost related to the therapy
• The acquisition will strengthen Covis respiratory portfolio with the addition of Eklira & Duaklir. Additionally, both therapies are delivered via a Genuair device that is used for the treatment of patients with COPD
• Eklira is marketed as Bretaris while Duaklir as Brimica in some countries & both are inhaled respiratory therapies. In 2018, Covis has previously acquired the rights from AstraZeneca to the respiratory medicines i.e., Alvesco, Omnaris, and Zetonna

Ref: AstraZeneca | Image: Reuters